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Safety and eﬃ  cacy of diaphragm pacing in patients with 
respiratory insuﬃ  ciency due to amyotrophic lateral sclerosis 
(DiPALS): a multicentre, open-label, randomised controlled 
trial 
DiPALS Writing Committee, on behalf of the DiPALS Study Group Collaborators*
Summary
Background Non-invasive ventilation is part of the standard of care for treatment of respiratory failure in patients 
with amyotrophic lateral sclerosis (ALS). The NeuRx RA/4 Diaphragm Pacing System has received Humanitarian 
Device Exemption approval from the US Food and Drug Administration for treatment of respiratory failure in 
patients with ALS. We aimed to establish the safety and eﬃ  cacy of diaphragm pacing with this system in patients 
with respiratory muscle weakness due to ALS.
Methods We undertook a multicentre, open-label, randomised controlled trial at seven specialist ALS and respiratory 
centres in the UK. Eligible participants were aged 18 years or older with laboratory supported probable, clinically 
probable, or clinically deﬁ nite ALS; stable riluzole treatment for at least 30 days; and respiratory insuﬃ  ciency. We 
randomly assigned participants (1:1), via a centralised web-based randomisation system with minimisation that 
balanced patients for age, sex, forced vital capacity, and bulbar function, to receive either non-invasive ventilation 
plus pacing with the NeuRx RA/4 Diaphragm Pacing System or non-invasive ventilation alone. Patients, carers, and 
outcome assessors were not masked to treatment allocation. The primary outcome was overall survival, deﬁ ned as 
the time from randomisation to death from any cause. Analysis was by intention to treat. This trial is registered, 
ISRCTN number 53817913.
Findings Between Dec 5, 2011, and Dec 18, 2013, we randomly assigned 74 participants to receive either non-invasive 
ventilation alone (n=37) or non-invasive ventilation plus diaphragm pacing (n=37). On Dec 18, 2013, the Data Monitoring 
and Ethics Committee (DMEC) recommended suspension of recruitment on the basis of overall survival ﬁ gures. 
Randomly assigned participants continued as per the study protocol until June 23, 2014, when the DMEC advised 
discontinuation of pacing in all patients. Follow-up assessments continued until the planned end of the study in 
December, 2014. Survival was shorter in the non-invasive ventilation plus pacing group than in the non-invasive 
ventilation alone group (median 11·0 months [95% CI 8·3–13·6] vs 22·5 months [13·6–not reached]; adjusted hazard 
ratio 2·27, 95% CI 1·22–4·25; p=0·009). 28 (76%) patients died in the pacing group and 19 (51%) patients died in the 
non-invasive ventilation alone group. We recorded 162 adverse events (5·9 events per person-year) in the pacing group, 
of which 46 events were serious, compared with 81 events (2·5 events per person-year) in the non-invasive ventilation 
alone group, of which 31 events were serious.
Interpretation Addition of diaphragm pacing to standard care with non-invasive ventilation was associated with 
decreased survival in patients with ALS. Our results suggest that diaphragmatic pacing should not be used as a 
routine treatment for patients with ALS in respiratory failure.
Funding The National Institute for Health Research Health Technology Assessment Programme; the Motor Neurone 
Disease Association of England, Wales, and Northern Ireland.
Copyright © DiPALS Study Group Collaborators. Open Access article distributed under the terms of CC-BY-NC-ND 4.0.
Introduction
Amyotrophic lateral sclerosis (ALS), also known as motor 
neuron disease, is a neurodegenerative disorder in which 
death occurs on average 3 years after symptom onset, in 
most cases because of respiratory failure.1 The only 
disease-modifying treatment is riluzole, a glutamate-
release modulator, which improves survival by an average 
of 3 months.2,3 Non-invasive ventilation is part of the 
standard of care for treatment of respiratory failure in 
patients with ALS, extending life by an average of 
7 months.4 However, non-invasive ventilation is not 
without problems, and claustrophobia, problems in the 
interface between device and patient, a physical barrier to 
communication, asynchrony between non-invasive 
ventilation and patients’ natural breathing, a fairly poor 
uptake in patients with bulbar dysfunction, and concerns 
about increasing aspiration of secretions lead to 
adherence rates of roughly 72%.5,6 Therefore, an 
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alternative or com plementary means of maintaining or 
supporting respiratory function is highly appealing.
Diaphragm pacing or, more accurately, phrenic nerve 
stimulation leading to contraction of the diaphragm, has 
historically largely been used in patients with spinal cord 
injury. Challenges with this approach have been the 
signiﬁ cant risk of iatrogenic phrenic nerve injury and, 
until recently, the need to undertake a thoracotomy.7 The 
NeuRx RA/4 Diaphragm Pacing System (Synapse 
Biomedical, Oberlin, OH, USA) has an advantage 
compared with the earlier approach in that the phrenic 
nerves are stimulated near the motor endpoints within 
the diaphragm muscle.8 Therefore, a minimally invasive 
laparoscopic abdominal procedure can be used to insert 
the electrodes into the undersurface of the diaphragm.
Case series of the spinal cord injury and ALS 
populations have emphasised the apparent simplicity 
and operative safety of the NeuRx RA/4 Diaphragm 
Pacing System.9,10 Data from an uncontrolled multicentre 
cohort study led to Humanitarian Device Exemption 
approval of the Diaphragm Pacing System from the US 
Food and Drug Administration (FDA).11 Since this 
approval on humanitarian grounds, insertion of the 
NeuRx RA/4 Diaphragm Pacing System as a treatment 
for respiratory failure in patients with ALS has become 
frequent practice worldwide. Although the evidence to 
date suggests that insertion of the NeuRx RA/4 
Diaphragm Pacing System is a fairly straightforward 
procedure, and despite the encouraging provisional data 
for the beneﬁ ts of diaphragm pacing, we and others12 
recognised the need to establish, by means of a 
randomised controlled trial, the long-term safety amd 
eﬃ  cacy of diaphragm pacing with the NeuRx RA/4 
Diaphragm Pacing System when used in addition to 
non-invasive ventilation, compared with the standard 
care of non-invasive ventilation alone.12
Methods
Study design and participants
We did this multicentre, open-label, randomised 
controlled trial at seven specialist ALS and respiratory 
centres in the UK. The full protocol is described 
elsewhere.13 Participants aged 18 years or older were 
eligible for inclusion if they had laboratory supported 
probable, clinically probable, or clinically deﬁ nite ALS, 
according to the World Federation of Neurology revised 
El Escorial criteria;14 were stabilised on riluzole treatment 
for at least 30 days; had respiratory insuﬃ  ciency as 
determined by one or more of forced vital capacity (FVC) 
less than 75% predicted, supine vital capacity less than 
75% of sitting or standing vital capacity, sniﬀ  nasal 
inspiratory pressure less than 65 cm H2O (men) or 55 cm 
H2O (women) in the presence of symptoms, sniﬀ  nasal 
inspiratory pressure less than 40 cm H2O, partial carbon 
dioxide pressure (PaCO2) of more than 6 kPa (daytime) or 
6·5 kPa (overnight), or signiﬁ cant overnight O2 
desaturation (>5% of night with oxygen saturation <90% 
during overnight oximetry); and had clinically acceptable 
bilateral phrenic nerve function, deﬁ ned either by the 
absence of paradoxical abdominal wall movement during 
a supine sniﬀ  manoeuvre (sharp inhalation through the 
nose) and less than a 10% decline of FVC when moving 
from sitting to supine position, or by ultrasound evidence 
of at least 1 cm of downward diaphragm movement 
independent of thoracic or abdominal wall movement 
during a sniﬀ  manoeuvre.
Exclusion criteria were previous use of non-invasive 
ventilation; a pre-existing implanted electrical device; 
underlying cardiac disease, pulmonary disease, or other 
disorders that would aﬀ ect pulmonary tests in-
dependently of ALS, or increase the risk of general 
anaesthesia or adversely aﬀ ect survival over the course of 
the study; current pregnancy or breastfeeding; signiﬁ cant 
Research in context 
Evidence before this study
We searched PubMed for reports published before April 1, 
2015, with the terms “amyotrophic lateral sclerosis”, “motor 
neuron disease”, “ALS”, “MND”, and “diaphragm pacing”. We 
included all prospective studies of diaphragm pacing in 
patients with amyotrophic lateral sclerosis (ALS). We did not 
identify any randomised controlled studies. We identiﬁ ed one 
cohort study that has been partially reported in various 
publications, including in a summary of safety and probable 
beneﬁ t (SSPB) published after Humanitarian Device 
Exemption approval for diaphragm pacing from the US Food 
and Drug Administration. In the SSPB, median overall survival 
for implanted patients was 56 months (4·7 years) from 
disease onset and 19 months (1·6 years) from implantation. 
A subgroup of patients were matched with historical controls 
and  survival from diagnosis in the historical non-invasive-
ventilation control group (n=43) was 21·4 months compared 
with 37·5 months for non-invasive ventilation plus pacing 
(p<0·001). 
Added value of this study 
This is the ﬁ rst randomised controlled trial of non-invasive 
ventilation alone versus non-invasive ventilation plus pacing. 
Patients receiving diaphragm pacing had decreased survival, 
unlike those in the previous cohort study of a selected ALS 
population, which showed a beneﬁ t of diaphragm pacing. 
Implications of all the available evidence
Our ﬁ ndings suggest that diaphragm pacing should not be used 
as a treatment for patients with ALS at the point of respiratory 
failure. The disparity between our results and those of the 
previous uncontrolled cohort study demonstrates the 
importance of undertaking randomised controlled trials to 
identify beneﬁ ts and exclude harm of interventions, whether 
they are drugs or medical devices. 
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decision-making incapacity preventing informed 
consent; obesity aﬀ ecting surgical access to the dia-
phragm, or signiﬁ cant scoliosis or chest-wall deformity; 
involvement in any respiratory trial that could aﬀ ect the 
safety or outcome measures of this study within 3 months 
of the planned implantation of the device or during the 
year of follow-up; pre-existing diaphragm abnormality, 
such as a hiatus hernia or paraoesophageal hernia, 
leading to ascent of abdominal contents into the thoracic 
cavity; and an FVC of less than 50% predicted or a sniﬀ  
nasal inspiratory pressure of less than 30 cm H2O in 
patients unable to undergo FVC (eg, patients with bulbar 
muscular atrophy) because of potential anaesthetic risk. 
These criteria are consistent with the indications for use 
outlined in the FDA summary of safety and probable 
beneﬁ t (SSPB) report for the NeuRx RA/4 diaphragm 
pacing system.11
Patients provided written informed consent before 
screening or, for individuals unable to write, verbal 
consent was given and a witness signed to acknowledge 
the consent of the participant. The East of England 
Central Cambridge Research Ethics Committee provided 
ethics approval for the study (reference 11/EE/0226).
Randomisation and masking
We randomly assigned patients (1:1), via a central web-
based randomisation system, to receive either non-
invasive ventilation plus diaphragm pacing with the 
NeuRx RA/4 Diaphragm Pacing system or non-invasive 
ventilation alone (control group). The ﬁ rst ten parti-
cipants were allocated with simple randomisation and 
thereafter patients were allocated by non-deterministic 
minimisation (with an allocation probability of 0·8), 
balancing for age, sex, FVC, and bulbar function. 
Patients, carers, and outcome assessors were not masked 
to treatment allocation.
Procedures
Scheduled follow-up visits were at months 2, 3, 6, 9, and 
12 after randomisation. Sites were allowed to initiate 
non-invasive ventilation in both groups any time after 
commencing screening as per their standard practice. A 
minimum target of 4 h of overnight use of non-invasive 
ventilation was set for patients, who were encouraged to 
use non-invasive ventilation for as long as possible 
overnight and, if clinically required, during the daytime.  
For patients allocated to diaphragm pacing, surgery 
was scheduled for as soon as was practicable after 
randomisation. Before surgery, a preoperative assess-
ment was done to ensure the respiratory criteria for 
each patient remained within the safe range for 
anaesthesia (FVC ≥45%, sniﬀ  nasal inspiratory pressure 
≥30 cm H2O) and to ensure that they were otherwise 
safe to undergo the procedure. The procedure for 
insertion of the NeuRx RA/4 Diaphragm Pacing System 
was done as previously described and is detailed in the 
appendix.9,10,13 
The initial target for pacing sessions was ﬁ ve times per 
day, with each session lasting at least 30 min. Patients 
were advised to build up to this target over the ﬁ rst 
month. In the second month, patients were asked to 
gradually lengthen the pacing sessions. When using the 
pacing system for 6–7 h a day, patients were advised to 
switch from pacing during the day to pacing overnight 
whilst asleep. At this stage patients were allowed to use 
the pacing device additionally during the day if they 
experienced beneﬁ t. Adherence to target use of 
diaphragm pacing and non-invasive ventilation was 
recorded by a study nurse at each follow-up in a patient 
diary and also at each follow-up visit, at which patients 
were asked how much they had paced or used non-
invasive ventilation on a typical day that they identiﬁ ed 
within the previous week; use was categorised post hoc 
as high use (≥4·0 h per day), low use (1·0–3·9 h), or no 
use (<1 h). Usage data for non-invasive ventilation were 
downloaded from non-invasive ventilation machines 
when available. Means were calculated from the machine 
data and diary data available since the previous study 
visit.
759 screened for eligibility
37 analysed 37 analysed
37 allocated to non-invasive ventilation
37 received allocated intervention
 
  
 
 
 
 
74 randomly assigned
 
685 excluded
539 ineligible
160 not yet in respiratory failure
93 FVC or SNIP too low
74 previous non-invasive ventilation
23 not on riluzole
21 unconfirmed ALS diagnosis
168 other or not known
95 declined to participate
51 in screening at trial termination
37 allocated to diaphragm pacing plus 
non-invasive ventilation
32 received allocated intervention
5 did not undergo surgery
2 at DMEC recommendation
2 patient choice
1 rapid decline in respiratory function
5 discontinued intervention before 
implantation
2 at DMEC recommendation
2 patient choice
1 had technical problems with device
Figure 1: Trial proﬁ le 
FVC=forced vital capacity. SNIP=sniﬀ  nasal inspiratory pressure. DMEC=Data Monitoring and Ethics Committee. 
ALS=amyotrophic lateral sclerosis.
See Online for appendix
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Outcomes 
The primary outcome was overall survival, deﬁ ned as the 
time from randomisation to death from any cause. 
Secondary outcomes were: patient quality of life (assessed 
with the 36-item Short Form Health Survey [SF-36] and 
the Sleep Apnoea Quality of Life [SAQLI] questionnaire); 
carer quality of life (Caregiver Burden Inventory); cost-
utility analysis (the Euroqol 5D questionnaire 3-level 
format [EQ-5D-3L]15) and health-care resource use; and 
tolerability and adverse events. Categorisation of adverse 
events was done with no knowledge of treatment 
allocation. A post-hoc analysis of tracheostomy-free 
survival (ie, the time from randomisation to the insertion 
of tracheostomy or death) was done to aid comparability 
with other studies of ALS.
Statistical analysis 
The trial was powered to detect a 12 month survival 
improvement from 45% to 70%, corresponding to a hazard 
ratio (HR) of 0·45. With a schedule of 18 months’ 
recruitment, 12 months’ follow-up, and control group 
survival of 20% at 24 months and 10% at 30 months, 
108 patients (54 per group) were needed to record the 
64 events required by the log-rank test, with 85% power, a 
two-sided type I error of 5%, and 10% additional dropout.16 
We analysed overall survival and tracheostomy-free 
survival with Cox regression, with minimisation factors as 
covariates. We did a sensitivity analysis with the log-rank 
test stratiﬁ ed by centre. We analysed quality of life with a 
longitudinal model (generalised least squares) with 
baseline quality of life and minimisation factors as 
covariates. Missing data were imputed for survivors, ﬁ rst 
by interpolation if possible, and otherwise by multiple 
imputation. For further analysis of EQ-5D-3L, we used an 
imputed score of zero for timepoints following participant 
death. Analyses were by intention to treat, with pre-
planned secondary analyses of overall survival based on 
protocol adherence and usage of non-invasive ventilation. 
Additional unplanned analyses of survival in relation to 
non-invasive ventilation and pacing usage were added 
thereafter. There was no planned interim analysis. The 
trial was overseen by an independent Trial Steering 
Committee and an independent Data Monitoring and 
Ethics Committee (DMEC). The DMEC monitored the 
results provided by the trial statistician with reference to 
safety. During this monitoring, a potential safety signal 
was identiﬁ ed and an unplanned interim survival analysis 
was done. Additional post-hoc (exploratory) analyses were 
subsequently added to investigate whether this signal 
could be explained by other factors, in particular, by use of 
non-invasive ventilation. We did analyses with Stata 
(version 12.1) and primary analyses were veriﬁ ed with SAS 
(version 9.4).17 This study is registered, ISRCTN number 
53817913.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. All authors had full access to all the 
data in the study and the corresponding author had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Figure 1 shows the trial proﬁ le. Between Dec 5, 2011, and 
Dec 18, 2013, we randomly assigned 74 participants to 
receive either non-invasive ventilation alone (n=37) or 
non-invasive ventilation plus diaphragm pacing (n=37; 
ﬁ gure 1). On Dec 18, 2013, the DMEC recommended that 
recruitment be suspended on the basis of a concerning 
 Non-invasive ventilation plus 
diaphragm pacing group (n=37)
Non-invasive ventilation 
alone group (n=37)
Centre
Leeds 2 (5%) 5 (14%)
London 1 (3%) 1 (3%)
Manchester 6 (16%) 4 (11%)
Newcastle 6 (16%) 2 (5%)
Oxford 11 (30%) 13 (35%)
Plymouth 3 (8%) 3 (8%)
Sheﬃ  eld 8 (22%) 9 (24%)
Age* 60 (10) 54 (12)
Sex*
Male 29 (78%) 29 (78%)
Female 8 (22%) 8 (22%)
FVC (%)*† 66·1 (12·3) 64·6 (12·1)
ALS type
Sporadic 34 (92%) 35 (95%)
Familial 3 (8%) 2 (5%)
ALS diagnosis
Clinically deﬁ nite 26 (70%) 22 (59%)
Clinically probable 7 (19%) 9 (24%)
Clinically probable, laboratory supported 4 (11%) 6 (16%)
Site of ALS onset 
Limb 26 (70%) 28 (76%)
Bulbar 10 (27%) 6 (16%)
Respiratory 1 (3%) 1 (3%)
Mixed 0 2 (5%)
Bulbar score*
Mild (9–12) 26 (70%) 29 (78%)
Moderate (5–8) 8 (22%) 6 (16%)
Severe (0–4) 3 (8%) 2 (6%)
Time from symptom onset (months) 22 (18) 22 (15)
<12 12 (32%) 14 (38%)
12–24 14 (28%) 12 (32%) 
>24 11 (30%) 11 (30%)
Rate of decline per month‡ 0·99 (0·68) 0·94 (0·71)
Data are n (%) or mean (SD), unless otherwise indicated. ALS=amyotrophic lateral sclerosis. FVC=forced vital capacity 
(reported as the percentage of prediced FVC). *Minimisation factors. †Two participants had no FVC data recorded; 
their sniﬀ  nasal inspiratory pressure results were 53 cm H2O (pacing) and 34 cm H2O (control). ‡Calculated as 
(48–baseline ALS Functional Rating Scale-Revised)/(months since onset). 48 is the maximum possible score on the ALS 
Functional Rating Scale-Revised. If the patient is assumed to have the maximum score at onset, the result of the 
calculation represents the mean change per month.
Table 1: Baseline demographic and clinical characteristics
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signal in the overall survival ﬁ gures. Patients in the study 
already receiving diaphragm pacing continued with this 
intervention as per the study protocol. However, after 
randomisation, two patients who had been allocated to 
diaphragm pacing and were awaiting implantation had 
their surgery cancelled. The DMEC made the 
recommendation to end active pacing in all participants 
on June 23, 2014, and to continue follow up until the 
planned end of the study. Study follow-up concluded on 
Dec 3, 2014, at which time 47 patients had died; one 
patient was last followed up on Aug 4, 2014, with the 
remaining 26 patients alive at study close. 
Patients in the pacing group were on average older 
than those in the non-invasive ventilation alone group, 
but otherwise baseline characteristics were similar 
between groups (table 1). Survival from randomi sation 
was shorter in the non-invasive ventilation plus pacing 
group versus the non-invasive ventilation alone group 
(table 2, ﬁ gure 2). Results were relatively unchanged 
when analysis was adjusted for study site (table 2). The 
unadjusted HR and the HR stratiﬁ ed by centre were 
similar (table 2). Only one patient underwent a 
tracheostomy (non-invasive ven tilation plus pacing 
group, 31 months after randomisation); therefore, 
tracheostomy-free survival was very similar to overall 
survival (table 2). Median survival from symptom onset 
was 28 months (95% CI 22–45) for patients receiving 
diaphragm pacing and 45 months (32–not reached) for 
those receiving non-invasive ventilation alone.
Non-invasive ventilation was initiated in 70 (95%) of 
74 patients: 57 (81%) patients started treatment within 
2 weeks of randomisation, a further six (9%) patients 
started within 1 month, and the remaining seven (10%) 
patients started between 3 months and 11 months 
Non-invasive ventilation plus 
diaphragm pacing group (n=37)
Non-invasive ventilation 
alone group (n=37)
Hazard ratio or mean 
diﬀ erence* (95% CI)
p value
Primary outcome 
Overall survival (months) 11·0 (8·3 to 13·6) 22·5 (13·6 to not reached) 2·28 (1·27 to 4·10) 0·006
Adjusted for minimisation covariates ·· ·· 2·27 (1·22 to 4·25) 0·009
Stratiﬁ ed by site ·· ·· 2·02 (1·21 to 3·84) 0·012
Secondary outcomes
SF-36 (% complete†) 110/154 (72%) 133/174 (76%) ·· ··
Aggregate physical health score 23·8 (12·2) 21·3 (12·0) 0·3 (–2·0 to 2·7) 0·780
Aggregate mental health score 42·7 (16·5) 47·7 (17·8) –3·5 (–7·9 to 0·8) 0·112
SAQLI (% complete†) 110/154 (72%) 132/174 (76%) ·· ··
Score 3·9 (1·6) 4·6 (1·5) –0·3 (–0·7 to 0·1) 0·117
Caregiver Burden Inventory (% complete†) 93/154 (60%) 121/174 (70%)
Score 28·0 (9·0) 29·6 (11·9) 1·2 (–2·7 to 5·0) 0·558
Post-hoc analyses of primary outcome
Overall survival by use of non-invasive ventilation (unadjusted)
No use (<1·0 h) 7·7 (3·4 to 11·6) Not reached‡ 4·67 (1·50 to 14·5) 0·008
Low use (1·0–3·9 h) 10·9 (6·3 to not reached) 13·6 (11·3 to not reached) 1·28 (0·34 to 4·8) 0·719
High use (≥4·0 h) 13·6 (5·3 to 19·1) 17·1 (10·8 to 30·1) 1·67 (0·70 to 3·97) 0·246
Tracheostomy-free survival 11·0 (8·3 to 13·6) 22·5 (13·6 to not reached) 2·42 (1·28 to 4·59) 0·007
Post-hoc analyses of patient quality of life
EQ-5D-3L health state (% complete†) 131/178 (74%) 161/209 (77%) ·· ··
Survivors 0·02 (0·37) 0·13 (0·44) –0·12 (–0·24 to –0·00) 0·056
All patients (zero assigned from death onwards) 0·01 (0·19) 0·11 (0·29) –0·14 (–0·24 to –0·04) 0·001
EQ-5D-3L thermometer scale (% complete†) 132/178 (74%) 160/209 (77%) ·· ··
Survivors 36·0 (25·2) 40·0 (25·7) –5·6 (–14·5 to 3·2) 0·212
All patients (zero assigned from death onwards) 14·8 (22·9) 27·4 (28·7) –12·0 (–20·8 to –3·1) 0·008
Post-hoc analyses of carer quality of life§
EQ-5D-3L health state (% complete†) 109/178 (61%) 148/209 (71%) ·· ··
Score 0·78 (0·34) 0·82 (0·25) –0·08 (–0·17 to 0·01) 0·077
EQ-5D-3L thermometer scale (% complete†) 110/178 (62%) 149/209 (71%) ·· ··
Score 81·3 (22·6) 71·0 (27·7) –0·2 (–7·4 to 7·1) 0·966
Data are median (95% CI) for survival outcomes and mean (SD) for quality of life (SF-36, SAQLI, Caregiver-Burden Inventory, and EQ-5D-3L), unless otherwise indicated. 
EQ-5D-3L=EuroQol 5D questionnaire 3-level format. SF-36=36-item Short Form Health Survey. SAQLI=Sleep Apnoea Quality of Life questionnaire.*Mean diﬀ erences from 
longitudinal analysis of quality-of-life measures. †Completeness is number of questionnaires obtained within time windows as a ratio of the number expected (ie, not 
including post-death). ‡Median survival not reached. §Not all participants had assigned carers. 
Table 2: Survival and quality of life outcomes
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(table 3). Non-invasive-ventilation usage was similar 
between groups (table 3). The appendix shows the asso-
ciation between adherence to non-invasive ven tilation 
and overall survival. Although the diﬀ erence between the 
non-invasive ventilation plus pacing and the non-invasive 
ventilation alone groups was greatest in the non-users 
subgroup, pacing was not more eﬀ ective in any of the 
three subgroups of high, low, or no use (table 2). The 
association between overall survival and average non-
invasive ventilation use was non-signiﬁ cant, with the HR 
for the linear association 0·97 per additional hour use 
(95% CI 0·92–1·04; p=0·52). No association was evident 
with pacing use (HR 1·00 per additional hour use, 95% CI 
0·92–1·09; p=0·92).
Five (14%) participants in the pacing group did not 
undergo surgery because of a rapid decline in respiratory 
function to lower than the safety threshold for surgery 
(n=1), patient choice (n=2), and the DMEC intervention 
(n=2); a sixth patient had technical problems with the 
device and did not begin regular pacing (ﬁ gure 1, table 3). 
Exclusion of these patients from the analysis did not 
change the ﬁ ndings, with the adjusted HR increasing 
when non-users were excluded (HR 2·71, 95% CI 
1·39–5·27). All participants who underwent surgery had 
a successful implantation and a diaphragm that could be 
stimulated. When used, median daily usage was 4·6 h 
(IQR 3·0–8·4 h), with no association between daily use 
and survival (table 3). Most participants receiving 
diaphragm pacing were able to achieve the target pacing 
settings within 15 days of surgery and continued to titrate 
successfully over the course of the study as per the study 
protocol (table 3, appendix). Pacing was well tolerated, 
with only two (5%) patients choosing to discontinue 
pacing at months 6 and 12 after starting regular use.
The patient health utility (EQ-5D-3L) score was slightly 
lower with diaphragm pacing plus non-invasive ven tilation 
than with non-invasive pacing alone, and the diﬀ erences 
were signiﬁ cant when a score of zero was imputed to EQ-
5D-3L after death (table 2, appendix). Other patient quality-
of-life questionnaires were similar between the two groups, 
as were all carer quality-of-life measures (table 2, appendix). 
More adverse events were reported in the non-invasive 
ventilation plus pacing group than in the non-invasive 
ventilation alone group (162 events [5·9 events per person-
year] vs 81 events [2·5 events per person-year]; table 4). 
More patients had serious adverse events in the pacing 
group than in the non-invasive ventilation alone group 
(table 4). No patients died within 30 days of procedure; 
table 4 shows causes of death. 
A separate cost-utility analysis was planned; however, 
in view of the low eﬃ  cacy of diaphragmatic pacing, this 
analysis did not proceed. We have included the quality-of-
life component of the planned cost-utility analysis from 
the EQ-5D-3L to complement the SF-36 and SAQLI data. 
The appendix shows data for health-care resource use. 
Notably, the number of patients using aids (cough-assist 
devices, breath stacking, and suction machines) was 
similar between groups, but those who did use a 
mechanical cough-assist device or a suction machine 
tended to do so more in the non-invasive ventilation 
Non-invasive ventilation 
plus diaphragm pacing 
group (n=37)
Non-invasive 
ventilation alone 
group (n=37)
Initiated non-invasive ventilation 35 (95%) 35 (95%)
Time of initiation
During screening or on date of randomisation 13 (37%) 14 (40%)
1–14 days post-randomisation 16 (46%) 14 (40%)
15–28 days post-randomisation 2 (6%) 3 (9%)
>28 days post-randomisation 4 (11%) 4 (11%)
Use of non-invasive ventilation  
Mean time (h) 5·2 (5·1) 4·8 (4·6)
Median time (h) 3·2 (0·5–8·2) 4·6 (0·0–7·8)
No use (<1 h) 10/34 (29%) 10/34 (29%)
Low use (1–3·9 h) 8/34 (24%) 6/34 (18%)
High use (≥4 h) 16/34 (47%) 18/34 (53%)
Patients using diaphragm pacing 31 (84%) 0
Patients not using diaphragm pacing 6 (16%) NA
Did not undergo surgery 5 NA
Withdrew with minimum usage after technical 
problems
1 NA
Time to surgery (days; n=32 implanted)
Within 14 5 (16%) NA
15–28 12 (38%) NA
29–56 10 (31%) NA
>56 5 (16%) NA
Use of diaphragm pacing
Mean time (h) 6·2 (4·6) NA
Median time (h) 4·6 (3·0–8·4) NA
Data are n (%), n/N (%), mean (SD), or median (IQR), unless otherwise indicated. NA=not applicable.
Table 3: Average daily use of non-invasive ventilation and diaphragm pacing after initiation
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Figure 2: Overall survival
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alone group, and those who used breath stacking tended 
to do so more in the pacing group (appendix).
Discussion
Our ﬁ ndings show that addition of diaphragm pacing to 
the standard care of non-invasive ventilation was 
associated with decreased survival in patients with ALS. 
This result is in contradiction with the FDA SSPB, which 
reported a survival advantage for diaphragm pacing of 
16·1 months from symptom onset and 9 months from 
the point of initiation of non-invasive ventilation, 
compared with non-invasive ventilation alone in a 
historical cohort.11,18 Median survival from symptom 
onset in our study was 45 months in the non-invasive 
ventilation group and 28 months in the pacing group, 
compared with 56 months in the SSPB pacing study.
The complete dataset from the uncontrolled multi centre 
cohort study that led to FDA approval of the NeuRx RA/4 
Diaphragm Pacing System on humanitarian grounds has 
to date not been published, although descriptions of safety 
and eﬃ  cacy are available for the ﬁ rst 16 patients enrolled 
in the pilot phase of that study.19 This partial reporting 
makes full understanding of the diﬀ erences in the 
reported outcomes  challenging. Some results are available 
within the FDA SSPB, in which 144 patients were reported 
to have been enrolled to the pilot and pivotal phases of that 
cohort study. The primary inclusion criteria were evidence 
of residual bilateral phrenic nerve function and an FVC of 
less than 85% at screening and more than 45% at 
implantation of the pacing system.11 106 (74%) of the 
144 participants were implanted with the Pacing System. 
Details of the 38 (26%) patients who did not undergo 
implantation are not reported.
To establish whether the NeuRx RA/4 Diaphragm 
Pacing System met the Humanitarian Device Exemption 
criteria in ALS, analyses for the FDA SSPB were done in 
a subgroup of the 106 patients who were implanted. For 
survival analyses, this subgroup consisted of 84 patients 
Non-invasive ventilation plus diaphragm pacing group (n=37) Non-invasive ventilation alone group (n=37)
Number 
of AEs 
Patients 
with an AE
Number 
of SAEs
Patients 
with an SAE
Number 
of AEs 
Patients 
with an AE
Number 
of SAEs 
Patients 
with an SAE
Any event 162 29 (78%) 46 27 (73%) 81 23 (62%) 31 19 (51%)
Respiratory 45 25 (68%) 29 21 (57%) 19 14 (38%) 13 11 (30%)
Chest infection 20 12 (32%) 10 9 (24%) 11 7 (19%) 6 5 (14%)
Decompensated respiratory failure 10 10 (27%) 10 10 (27%) 5 5 (14%) 5 5 (14%)
Breathless (unclassiﬁ ed) 5 4 (11%) 2 2 (5%) 3 2 (5%) 2 1 (3%)
Pneumothorax or capnothorax 5 5 (14%) 3 3 (8%) 0 0 0 0
Blocked airway 3 1 (3%) 3 1 (3%) 0 0 0 0
Pulmonary embolism 1 1 (3%) 1 1 (3%) 0 0 0 0
Cough 1 1 (3%) 0 0 0 0 0 0
Pain 23 10 (27%) 1 1 (3%) 10 6 (16%) 3 2 (5%)
Gastrointestinal 17 10 (27%) 3 3 (8%) 12 9 (24%) 2 2 (5%)
Symptoms of motor neuron disease 18 8 (22%) 1 1 (3%) 7 3 (8%) 0 0
Insertion or removal of PEG or PIG 9 5 (14%) 6 4 (11%) 10 9 (24%) 9 8 (22%)
Genitourinary 7 3 (8%) 0 0 8 3 (8%) 1 1 (3%)
Infection of PEG or PIG 10 3 (8%) 0 0 2 1 (3%) 0 0
Dermatological 6 3 (8%) 0 0 4 4 (11%) 1 1 (3%)
Wire problems 8 5 (14%) 2 2 (5%) 0 0 0 0
Cardiovascular system 4 4 (11%) 3 3 (8%) 2 2 (5%) 1 1 (3%)
Psychiatric 5 4 (11%) 0 0 0 0 0 0
Non-invasive-ventilation speciﬁ c 3 3 (8%) 0 0 2 2 (5%) 0 0
Wire infection 4 3 (8%) 0 0 0 0 0 0
CNS 1 1 (3%) 0 0 1 1 (3%) 0 0
Other 2 2 (5%) 1 1 (3%) 4 3 (8%) 1 1 (3%)
Deaths
Cause of death
Respiratory failure ·· ·· ·· 16/28 ·· ·· ·· 13/19
Chest infection ·· ·· ·· 5/28 ·· ·· ·· 2/19
ALS ·· ·· ·· 6/28 ·· ·· ·· 4/19
Hypothermia ·· ·· ·· 1/28 ·· ·· ·· 0
Data are n (%) or n/N (%), unless otherwise indicated. AE=adverse event. SAE=serious adverse event. PEG=percutaneous endoscopic gastrostomy. PIG=per-oral image-guided 
gastrostomy. ALS= amyotrophic lateral sclerosis. 
Table 4: Adverse events
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who met the criteria for Humanitarian Use Device 
Designation (designation number 10-0242)—ie, patients 
with ALS with a stimulatable diaphragm and who had 
chronic hypoventilation. The deﬁ nition used for chronic 
hypoventilation was an FVC of less than 50%, a 
maximum inspiratory pressure less than 60 cm H2O, a 
PaCO2 greater than 45 mm Hg, or oxygen saturation less 
than 88% for 5 consecutive minutes or more overnight. 
Mean overall survival for implanted patients was 56 
months (4·7 years) from disease onset and 19 months 
(1·6 years) from implantation. No separate control group 
was included and the study team compared their data 
with a previously published historical survival dataset for 
non-invasive ventilation.18 For this comparison, the 
investigators selected patients (N=43) from the 
Humanitarian Use Designation group with an FVC 
between 45% and 65%. Survival from diagnosis in the 
historical non-invasive-ventilation dataset (N=43) was 
21·4 months, compared with 37·5 months for the pacing 
and non-invasive ventilation group (p<0·001). Survival 
from initiation of non-invasive ventilation was 
11·9 months for the historical group and 20·9 months 
for the pacing and non-invasive ventilation group. 
The patient population in the present study is 
characteristic of the ALS population in terms of age, sex, 
site of onset, and proportion with a clear family history;20 
the population from which the subgroup data used in the 
FDA SSPB were obtained might be less generalisable to 
the wider ALS population.11 The cohort study contained a 
lead-in phase of 3 months during which time patients 
were monitored, and not all went on to have implantation. 
Because of the progressive nature of ALS, some patients 
might have become ineligible, with their FVC decreasing 
to less than the study implantation safety threshold of 
45% during the 3 months. This possibility might have 
enriched the implanted population with individuals who 
have a more slowly progressive disease course. However, 
whether such enrichment happened is not clear, and 
other criteria might have been used. Of the 106 patients 
who were implanted, data for only 84 patients contribute 
to the SSPB report, with two patients having been lost to 
follow-up and 20 patients not meeting the Humanitarian 
Use Device criteria. This cohort is therefore a selected 
group and might not be generalisable to the wider ALS 
population. By contrast, we used an intention-to-treat 
approach in which all consenting participants were 
analysed, including those who subsequently declined 
rapidly in either group.
The apparent harm recorded in the pacing group was 
not obviously due to immediate surgical complications, 
with no deaths within 30 days of procedure and only one 
within the ﬁ rst 3 postoperative months. However, a 
retrospective review of patients with ALS undergoing 
surgery for any cause showed an apparent acceleration of 
ALS disease progression post-surgery, suggesting a 
potential disease-modifying eﬀ ect, albeit one that is not 
fully understood.21 The survival diﬀ erences in our study 
might partly be explained by such a process, which 
supports previous wider concerns regarding the under-
taking of operative procedures in individuals with ALS. A 
further possibility is that the harm is due to a direct eﬀ ect 
of the pacing, perhaps because stimulation of already 
damaged motor neurons is harmful. The physiological 
eﬀ ects of pacing have not been studied in human beings. 
Findings from studies of canine and rodent models show 
that neuromuscular damage can be induced dependent 
on the parameters of pacing and that the eﬀ ects recorded 
diﬀ er between healthy and disease models.7,22 A simpler 
explanation could be that pacing causes excessive muscle 
fatigue, or that asynchrony between pacing-induced 
diaphragm contraction and breaths triggered by patients 
or non-invasive ventilation is an issue. We cannot exclude 
the possibility that a small subgroup of patients might 
beneﬁ t from diaphragm pacing. One particular group 
who might have most to gain from pacing would be low 
users of non-invasive ventilation—eg, patients with 
signiﬁ cant bulbar dysfunction. However, we noted the 
greatest diﬀ erence in survival in low users of non-
invasive ventilation; therefore, diaphragm pacing alone 
cannot be recom mended as an alternative to non-invasive 
ventilation. Because of the small sample size, we are 
unable to make meaningful attempts to investigate 
possible subgroup eﬀ ects further.
Our study has some limitations. Patients allocated to 
diaphragm pacing underwent surgical intervention and 
could not be masked to the intervention. The study 
assessors were also unmasked to the intervention. The 
trial statistician (MJB) was unmasked and gave survival 
data to the DMEC but withheld accumulating data from 
the study team. Because the primary outcome measure 
was objective (overall survival), the risk of bias is small, but 
some risk is unavoidable in the subjective patient-reported 
secondary outcome measures. We con sidered inserting 
the pacing devices in patients receiving non-invasive 
ventilation alone, but not connecting them (sham pacing), 
to reduce the risk of bias and be able to oﬀ er pacing to 
control patients at the end of the 12 month follow-up 
period, but concluded that this approach would be less 
rational in the event of an outcome showing no beneﬁ t of 
pacing. The eﬀ ect of pacing on the ongoing use of non-
invasive ventilation was a concern, and we asked whether 
patients stopped using the non-invasive ventilation system, 
which has established survival beneﬁ t, in favour of the 
pacing system. However, daily periods of non-invasive 
ventilation use were similar across both groups. Minor 
imbalances exist between the treatment groups in our 
study, with patients in the pacing group being slightly 
older than those in the non-invasive ventilation alone 
group. We have adjusted the hazard ratios for the covariate 
of age and propose that such a small age diﬀ erence is 
unlikely to have had a large eﬀ ect on ALS survival. Similar 
numbers of patients across each group were reported to 
receive additional respiratory interventions. However, we 
noted diﬀ erences across the treatment groups in the 
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frequency of use of cough-assist devices, suction machines, 
and breath-stacking techniques among individuals given 
devices. The eﬀ ects of these diﬀ erences are unknown, but 
again, are unlikely to explain the poor survival in the non-
invasive ventilation plus pacing group.
In conclusion, diaphragmatic pacing should not be a 
routine treatment for patients with ALS in respiratory 
failure. A subgroup of patients might experience a 
beneﬁ t; however, this possibility should not be assumed. 
Our ﬁ ndings suggest that insertion of the NeuRx RA/4 
Diaphragm Pacing System at the point an individual 
with ALS develops respiratory insuﬃ  ciency is harmful. 
Whether there is a point earlier in the disease trajectory 
when implantation and pacing might be of beneﬁ t is 
unknown and is currently being investigated 
(ClinicalTrials.gov, number NCT01583088). A poor 
prognosis and the absence of curative treatment 
understandably encourage a nothing to lose approach in 
patients and some clinicians alike, with an attendant 
lowering of the standards of evidence needed to adopt a 
new intervention.23 Our ﬁ ndings show the potential for 
harm that can arise from adopting this approach. 
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